Healthcare

<!– end javascript to email the article

–>
 style=”font-weight:normal; font-size:14px; font-family:verdana,helvetica, arial, sans-serif; text-align:left”

Targeted News Service

By Targeted News Service

ALEXANDRIA, Va., Aug. 7 — Janssen Pharmaceutica, Beerse, Belgium, has been assigned a patent (8,232,101) developed by four co-inventors for an “identification of antigenic peptides from multiple myeloma cells.” The co-inventors are Zeling Cai, San Diego, Wei-Xing Shi, San Diego, Xuejun P. Liu, San Diego, and Jiejun Wu, San Diego.

The abstract of the patent published by the U.S. Patent and Trademark Office states: “Multiple myeloma (MM) is a clonal B cell malignancy and remains essentially incurable by conventional anti-tumor therapy. Patients with MM have a median survival of only three years. MM is characterized by proliferation and accumulation of mature plasma cells in the bone marrow (BM) leading to bone destruction, BM failure, anemia, and reduced immune function. The identification of MHC Class I, HLA-A2, associated peptides presented on multiple myeloma cells is an important step in developing immunotherapies for MM. Presented here are methods for creating activated T lymphocytes that are cytotoxic to both peptide loaded T2 target cells and multiple myeloma cell lines.”

The patent application was filed on Oct. 31, 2011 (13/285,459). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1Sect2=HITOFFd=PALLp=1u=%2Fnetahtml%2FPTO%2Fsrchnum.htmr=1f=Gl=50s1=82,32,101.PN.OS=PN/82,32,101RS=PN/82,32,101

Written by Kusum Sangma; edited by Anand Kumar.

KS0807AK0807-768994

Article source: http://www.equities.com/news/headline-story?dt=2012-08-07&val=351269&cat=hcare